Dopamine agonists and audiogenic seizures: the relationship between protection against seizures and changes in monoamine metabolism.
D000161:Acoustic Stimulation; D000818:Animals; D001058:Apomorphine / Q000031:analogs & derivatives / Q000494:pharmacology; D001679:Biogenic Amines / Q000378:metabolism*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D001971:Bromocriptine / Q000494:pharmacology; D004298:Dopamine / Q000502:physiology*; D004873:Ergolines / Q000494:pharmacology; D004874:Ergonovine / Q000494:pharmacology; D005260:Female; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D011814:Quipazine / Q000494:pharmacology; D012640:Seizures / Q000517:prevention & control*
D001679:Biogenic Amines; D004873:Ergolines; D001971:Bromocriptine; D011814:Quipazine; D008238:Lysergic Acid Diethylamide; D001058:Apomorphine; D004298:Dopamine; D004874:Ergonovine